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Abstract 
 
Objective: To describe patient participation and clinical performance in a colorectal 
cancer (CRC) screening program utilising faecal occult blood test (FOBT).   
Methods: A community-based intervention was conducted in a small, rural 
community in North Queensland, 2000-2001. One of two FOBT kits – guaiac 
(Hemoccult-II) or immunochemical (!nform) – was assigned by general practice and 
mailed to participants (3358 patients aged 50-74 years listed with the local practices).  
Results: Overall participation in FOBT screening was 36.3%. Participation was 
higher with the immunochemical kit than the guaiac kit (OR=1.9, 95% CI: 1.6,2.2). 
Women were more likely to comply with testing than men (OR=1.4, 95% CI: 1.2,1.7), 
and people in their 60s were less likely to participate than those 70-74 years 
(OR=0.8, 95% CI: 0.6,0.9). The positivity rate was higher for the immunochemical 
(9.5%) than the guaiac (3.9%) test (2 = 9.2, p =0.002), with positive predictive values 
for cancer or adenoma of advanced pathology of 37.8% (95% CI: 28.1%, 48.6%) for 
!nform and 40.0% (95% CI: 16.8%, 68.7%) for Hemoccult-II. Colonoscopy follow-up 
was 94.8% with a medical complication rate of 2-3%.  
Conclusions: An immunochemical FOBT enhanced participation. Higher positivity 
rates for this kit did not translate into higher false-positive rates, and both test types 
resulted in a high yield of significant neoplasia. 
Implications:  In addition to type of FOBT, the ultimate success of a population-
based screening program for CRC using FOBT will depend on appropriate education 
of health professionals and the public as well as significant investment in medical 
infrastructure for colonoscopy follow-up. 
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Reducing mortality from colorectal cancer (CRC) is a national health priority.1,2 CRC 
is a significant burden for Australia, affecting about 10,000 Australians and causing 
about 4500 deaths per year.3,4 Randomised trials indicate that faecal occult blood test 
(FOBT) screening can reduce mortality rates by 15-35%,5-9 and there is considerable 
interest in a national screening program for Australia.  
 
FOBT screening is based on the principle that cancers bleed into the bowel, and that 
this bleeding may be detected. There are two main types of FOBTs: guaiac and 
immunochemical. Guaiac tests detect haem and haemoglobin, whereas 
immunochemical tests detect only intact human haemoglobin. To minimise false-
positive results, dietary restrictions are required when utilising a guaiac test. The 
large, clinical trials demonstrating reductions in CRC mortality were conducted with 
guaiac tests, namely Hemoccult and Hemoccult-II.10  Sensitivity of guaiac tests is 
usually between 50-80% and specificity is generally over 95%, increasing to 98-99% 
when dietary restrictions are followed.1,3 Test positivity rates for guaiac tests such as 
Hemoccult-II range from 1-5%.  The performance characteristics of immunochemical 
tests, such as HemeSelect, FlexSure OBT and !nform, are less well-established.11 
Reported specificity of immunochemical tests is slightly lower than guaiac tests at 95-
98%, but clinical sensitivity for cancer is generally higher. Immunochemical tests 
display positivity rates of 2-14%.11 
 
Reduction in CRC mortality rates from FOBT screening is enhanced by high 
participation levels in the community.12,13 Choice of kit is one factor that may influence 
participation. Dietary restrictions14 and perceptions of a test as ‘messy’ or 
‘disgusting’15 have been shown to significantly reduce participation. A simplified 
sampling process16 and a reduction in the number of required samples are associated 
with increased participation.17 This may indicate a preference for immunochemical 
tests, which have no dietary restrictions and are often designed to be more user-
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friendly. However people also tend to prefer the ‘status quo’ in relation to FOBT 
screening.18 In Australia, guaiac tests have been widely circulated by non-profit 
organisations such as Rotary and Lions – participants may therefore retain a 
preference for these tests.  
 
Few Australian studies have examined FOBT kit characteristics and participation in a 
community setting. Fewer still have assessed acceptability in a rural context.19,20 The 
present study was a demonstration project designed to describe FOBT screening 
participation in a rural community, comparing guaiac and immunochemical tests. In 
an effort to optimise participation, recruitment through general practitioners (GPs) 
was utilised.21-23  
  
Methods 
 
The participants 
 
A rural Queensland community was selected, with a population of approximately 
15,000 people (approximately 4,200 were aged 50 years or older).24 There were four 
general practices located in the region, with 10 GPs. The community is located within 
a 90-minute drive of an urban centre with the necessary infrastructure to support 
appropriate colonoscopic follow-up for those with a positive FOBT.  
 
GPs were thoroughly briefed on the research project and received copies of the 
National Health and Medical Research Council (NHMRC) guidelines for FOBT 
screening and follow-up.  All four practices in the selected community agreed to 
participate.  All patients aged 50 to 74 years listed with these practices were sent a 
BowelScreen intervention package.   
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The BowelScreen intervention 
 
The BowelScreen intervention package contained: a letter from the practice (signed 
by the practice doctors), a FOBT kit, instructions on using the kit, information about 
the research project, and an informed consent form. The !nform kit package also 
included an informational leaflet concerning bowel cancer and screening. The letter 
advised that the FOBT may not be suitable for patients with a family history 
(specifically, two or more first- or second-degree relatives on the same side of the 
family with CRC diagnosed at any age or at least one first-degree relative with CRC 
diagnosed before the age of 55), a personal history of CRC or polyps, or symptoms, 
and that such patients should consult with their GP.  
 
The kit was assigned by practice to minimise concerns related to two different kits 
being offered, particularly among members of a single household.  To optimise the 
numbers receiving each kit type, the largest and smallest practices were pooled as 
were the two middle-sized practices.  The two groups were then randomly allocated 
to kit type by flipping a coin.  Patients from the largest and smallest practices 
received the immunochemical kit, and patients from the other two practices received 
the guaiac test.  Those registered with more than one practice received multiple kits 
and were instructed to utilise the test-kit sent by the practice they usually attend. The 
initial mail-out was conducted in November 2000.  
 
The BowelScreen project was advertised in local newspapers on three occasions 
prior to and following the initial mail-out.  Posters were placed in the local general 
practices and pharmacies.  A reminder card was mailed to all non-respondents 
approximately 8 weeks after the initial mailing.  
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FOBT results were sent to both the practice and the patient. Individuals with a 
negative result were informed that no further action was required at this time and 
were encouraged to discuss a regular CRC screening program with their GP. Those 
with a positive result were instructed to make an appointment with their GP to 
discuss follow-up testing and were in most cases referred for colonoscopy. Those 
undergoing colonoscopy were followed up two or more weeks after the procedure to 
ascertain whether any complications had occurred. FOBT and colonoscopy were 
available at no cost to individuals in the project. 
 
The FOBT kits 
 
The immunochemical test, !nform (Enterix), requires no dietary restrictions. The test 
involves use of a brush to transfer toilet water from around the bowel motion to a test 
card for two consecutive motions. The completed test card can be sent through the 
mail to the laboratory for analysis. The guaiac test, Hemoccult-II (Beckman Coulter), 
requires participants to exclude certain items from their diet before and during 
testing, including red meat, certain vegetables, vitamin C and aspirin1. This test 
requires application of a faecal smear to a test card for three consecutive motions. 
Consequently it cannot be sent through the mail, and participants had to take their 
completed test cards to the local hospital for transport to the analytic laboratory. The 
!nform kits were analysed by the company that manufactures the test, and the 
Hemoccult-II kits were analysed at a government-funded hospital pathology 
laboratory. Hemoccult-II samples were not rehydrated. 
 
Data analysis 
 
Of the 3861 individuals contacted by the study, 503 (13.0%) received both 
immunochemical and guaiac kits. It was not possible to ascertain whether a kit was 
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being utilised/rejected because of instructions (i.e., participants were instructed to 
utilise the kit they received from the practice they usually attended) or individual 
preference. Consequently, participation rates by kit type could not be calculated for 
this sub-group and they were excluded from analyses, resulting in a sample size of 
3358.  In some instances, matching patient names appeared across practice lists 
with different addresses or date of birth information (n=25, 0.7%). For simplicity, 
these results assume that people with the same name are the same person. The 
gender of 12 persons (0.4%) and age information for 337 persons (10.0%) were 
unavailable. These individuals were subsequently excluded from gender-specific and 
age-specific analyses, respectively.  
  
Overall participation and participation with each kit type were calculated for 3358 
individuals. Interactions of kit type by gender or age were tested, but only the latter 
yielded differences. Positivity rates (blood identified in the sample) were recorded for 
both types of FOBT kit. Binary logistic regression models examined the association 
between the outcome variables, participation and positivity, and the independent 
variables kit type, gender and age-group. Statistical analyses were conducted with 
SPSS, version 11.5, and SUDAAN, version 7.5. 
 
Colonoscopy outcomes were reviewed by the project's consultant gastroenterologist 
(BL). The most severe diagnosis was identified for each patient. Stage of cancer, 
polyp number, size, location and histology were recorded. Adenomas were classified 
as adenoma of advanced pathology if they were 1 centimetre or more in diameter, 
had villous or tubulovillous histology or severe dysplasia. The positive predictive 
value for cancer or adenoma of advanced pathology was calculated. For those 
completing a kit, additional chi-square and logistic regression analyses were 
conducted to ascertain the relationships between a diagnosis of advanced pathology 
(i.e., cancer or an adenoma of advanced pathology) and kit type, gender and age. 
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Colonoscopy complications, ascertained from medical reports and individual 
interviews, were also recorded and reviewed by the gastroenterologist.  
 
Finally, we telephoned 88 of the 92 individuals who underwent colonoscopy to 
assess patients’ self-reported complications from the procedure. Three patients 
diagnosed with cancer and one undergoing barium enema were not contacted. 
Interview data were collected from 76 of these 88 patients (86.4%). Reasons for not 
obtaining complication information included: unable to contact after five attempts at 
different times of day (5), hearing problems (1), non-English speaking (2), unable to 
recall the procedure (1), unable to access telephone number (2), refusal (1). 
 
Ethical approval 
 
This study was approved by the University Human Research and Ethics Committee 
at the Queensland University of Technology. 
 
Results 
 
Of the 3358 individuals receiving a single kit type, 2419 (72.0%) received an 
immunochemical kit and 939 (28.0%) received a guaiac kit.  Overall, this represented 
contact with 92% of the census population24.  Because the age and gender 
distributions varied between kit groups (Table 1), multivariable analyses were 
conducted to adjust for these two demographic characteristics.   
 
Participation 
 
Overall, 1219 kits were completed and returned for analysis, yielding a participation 
rate of 36.3%.  Participation was significantly higher with the immunochemical kit (2 
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= 20.7, p<0.001), and women were significantly more likely to comply with testing 
than men (2 = 24.8, p<0.001) (Table 2).  Although there was no association between 
age and participation overall (2 = 4.4, p=0.11), kit type, gender and age were each 
significantly associated with participation in a model adjusting for all three factors 
(Table 2). In accordance with bivariate results, persons receiving an immunochemical 
kit were approximately twice as likely to participate than those receiving a guaiac kit. 
Women were 43% more likely to participate than men, irrespective of kit type (data 
not shown). 
 
The association between participation and age was significant at the multivariate 
level with younger age groups, particularly the 60-69 year olds, less likely to comply 
compared to the 70-74-year age-group. However, there was evidence of interaction 
between age and kit type (p=0.01; Figure 1). For those receiving the guaiac test, 
participation progressively increased with increasing age (27% among those 50-59; 
32% among those 60-69; and 35% among those 70-74 years). In contrast, among 
recipients of the immunochemical test, participation by the youngest (47%) and 
oldest (49%) age-groups were similar (OR = 0.98; 95% CI: 0.74 - 1.28 comparing 50-
59 year-olds and 70-74 year-olds) whereas persons aged 60-69 (40%) were less 
likely to participate (OR = 0.73; 95% CI: 0.56-0.96 relative to 70-74 year olds).  
 
Positivity rates and colonoscopy outcomes 
 
Of the 1219 kits returned, 100 tests (8.2%) were positive (i.e., blood was found in the 
faecal sample).  Positivity rates varied by kit type, from 3.9% for the guaiac test to 
9.5% for the immunochemical test (2= 9.2; p=0.002) (Table 3).   Multivariate models, 
adjusting for kit type, gender and age, revealed statistically significant associations 
with kit type and gender:  those receiving the immunochemical test were three times 
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more likely than those with the guaiac test to obtain a positive result (OR=3.05; 95% 
CI: 1.56-5.97); and women were less likely to test positive than men (OR=0.58; 95% 
CI: 0.38-0.88).  Positive FOBT results decreased with decreasing age after 
adjustment for kit type and gender (OR=0.60 for 50-59 year-olds and OR=0.77 for 
60-69 year-olds relative to 70-74 year-olds), but these results were not statistically 
significant. 
 
Three participants had medical reasons for not pursuing follow-up of a positive 
FOBT: clear colonoscopy in the last 12 months (1), or co-morbidity (2). Five patients 
refused colonoscopy, resulting in a compliance rate of 94.8% (92/97). The 
colonoscope was inserted to the caecum in 97.8% (90/92) of patients. One patient 
was examined to mid-rectum only, impeded by a cancer. The second patient was 
examined to the splenic flexure only, and was subsequently referred for barium 
enema obtaining a normal outcome.  
 
Colonoscopy outcomes by kit type are presented in Table 3. The most severe 
diagnosis for each participant is recorded. Two cancers were ACPS Stage B lesions 
in the sigmoid colon and the third was a Stage D lesion in the rectum. All three 
patients underwent surgery. In addition, two right hemicolectomies were performed 
for large, sessile, proximal adenomas that could not be removed colonoscopically. 
The positive predictive value for cancer or adenoma of advanced pathology was 
37.8% (95% CI: 28.1%, 48.6%) for the immunochemical test and 40.0% (95% CI: 
16.8%, 68.7%) for the guaiac test. 
 
Women were less likely than men, and those utilising the immunochemical kit were 
more likely that those using the guaiac kit, to receive a diagnosis of advanced 
pathology. However, these results were not statistically significant at either the 
bivariate or multivariate levels (Table 4). 
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Colonoscopy complications 
 
Medical records indicated two post-polypectomy bleeds but both settled without 
surgery. Three failed colonoscopies were recorded including: one heart failure from 
colonoscopy preparation; one failed colonoscopy, barium enema conducted; and one 
case where the instrument could not be passed through cancer. Of the 76 patients 
interviewed following colonoscopy, 66 (86.8%) reported no complications and 10 
reported complications, including: bleeding or pain (4); nausea or vomiting from the 
preparation liquid (2); nausea or vomiting following the procedure (3); and weight 
loss, fatigue and diarrhoea for several months following the procedure (1). The 
reports concerning nausea or vomiting pre- or post-procedure, weight loss, fatigue 
and diarrhoea were not noted in the specialist medical records.  
 
Discussion 
 
Participation was significantly higher with the immunochemical test kit, !nform, 
compared to the guaiac test kit, Hemoccult-II. Immunochemical testing resulted in a 
higher positivity rate than the guaiac test, but this did not translate into a higher false-
positive rate. Overall, participation with FOBT screening was modest (36.3%), with 
women more likely to undergo screening than men. Of those receiving positive FOBT 
results, only 5% declined appropriate clinical follow-up. A high incidence of significant 
pathology (38% diagnosed with CRC or advanced adenoma) was observed for those 
undergoing colonoscopy, and some complications were reported. A diagnosis of 
advanced pathology was not significantly associated with kit type, gender or age.  
 
Providing an immunochemical kit resulted in greater participation when compared to 
the guaiac kit. This difference was most apparent for those aged 50-59 years.  The 
 13
interpretation most consistent with the literature14-17 is that persons prefer the user-
friendly characteristics of the immunochemical test (e.g., more convenient, less 
messy, no dietary restrictions).  Discussion groups with study participants confirmed 
that these pragmatic aspects of testing were a consideration in participation.25  A 
telephone survey conducted prior to this study found that 17% of respondents 
indicated that dietary restrictions discourage them from taking the test, and this 
proportion increased with age and was particularly related to medication 
restrictions.26 The !nform kit package also included an information leaflet which may 
have increased compliance, however previous research has reported either no 
impact from educational leaflets or increased compliance in men only.27,29 Our results 
did not indicate an interaction between gender and kit type. In the interest of 
optimising participation, kit preferences within the community must be taken into 
account in any future, long-term, mass screening programs.  However, because the 
FOBT kits were offered free of charge in this study, we were unable to assess the 
extent to which cost may further influence participation in screening activities.  At the 
time of this study, the out-of-pocket costs for an individual to purchase an 
immunochemical kit were higher than the guaiac kits; yet, when laboratory and 
related expenses are taken into account, total costs were not very different.  
 
A modest participation rate with FOBT screening is consistent with the literature. 
Participation rates of 33-67% have been reported previously with a GP 
recommendation.19,20,23,27-31 Although conditions for participation were optimised by 
posting the FOBT kit directly to the home and covering virtually all costs associated 
with testing and follow-up, participation in the present study remained at the lower 
end of the published range. It also conflicted with reported intention to screen in this 
community, as 53% of participants in the earlier telephone survey indicated that they 
were ‘very likely’ or ‘likely’ to take part in a future FOBT screening.26  Only minimal 
efforts (poster, local newspaper advertisements) were made to promote the program. 
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Public awareness of CRC screening is in its infancy in Australia. In the telephone 
survey conducted prior to distribution of the FOBT kits,26 only 27% of respondents 
recognised the importance of screening for CRC in the absence of symptoms.  Like 
screening for other cancers, such as breast and cervical, it may take several years 
before the community recognises this test as legitimate and worthwhile.  
 
In addition, high levels of prior CRC testing in this community with tests other than 
FOBT may also account for a moderate participation rate. The baseline telephone 
survey indicated that 38% of respondents had undertaken a CRC test other than 
FOBT in the past, usually colonoscopy (29%).32  A recent colonoscopy would have 
made a FOBT unnecessary. Moreover, prior use of FOBT in this community was low 
(18%).26  Analyses of intention to participate in FOBT revealed that prior FOBT 
screening was the most significant predictor of further testing.32 During the discussion 
groups, both screening participants and non-participants questioned the efficacy of 
FOBT screening, revealing a preference for the greater certainty achieved with 
sigmoidoscopy and colonoscopy.25  This was echoed by some of the health 
professionals as well.25  Promotional activities therefore should particularly target 
first-time screeners by increasing a sense of familiarity with CRC screening and the 
use of FOBT as a selection device to indicate which individuals should progress to 
colonoscopy. Furthermore, informed consent, based on individualised assessment of 
potential benefits relative to possible risks, harms, and costs, is necessary for the 
proper conduct of a public health screening program.33  As individuals may have 
personal reasons for declining to participate in a CRC screening program, the 
process of informing potential participants requires additional attention to ensure 
informed consent.34,35 
 
Compliance with colonoscopy follow-up was high amongst those testing positive by 
FOBT, although the 5% who chose not to undergo colonoscopy is a concern.  This 
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study made provisions so that patients had access to prompt colonoscopy follow-up 
through private hospital services.  It also covered out-of-pocket expenses for those 
with insurance excesses and those without private health cover.  In a national, 
population-based program, access to timely colonoscopy services may be more 
problematic as a consequence of limitations in geographic availability of appropriate 
services and long waiting lists in the public sector. It is worthwhile to note that the 
threshold for a positive test can be set at different levels in immunochemical tests, 
allowing control of follow-up rates to match resource availability,36 although clearly 
this has ethical implications. 
 
There is controversy about what should be regarded a true-positive result of 
screening for CRC, and this study lacked statistical power to detect differences in this 
end-point. However, it is noteworthy that a high number of adenomas, and 
particularly adenomas of advanced pathology, were detected by both tests. 
Adenomas are found in up to 40% of asymptomatic subjects undergoing screening 
colonoscopy, but in such unselected subjects only a small percentage show 
advanced pathology.5,7 In general, the risk of an individual adenoma progressing to 
cancer has been estimated at 1 in 20: this risk may be considerably higher in 
adenomas of advanced pathology,37,38 hence removal of these seem likely to reduce 
the incidence of subsequent CRC.37,39 We therefore considered detection of either 
cancer or adenomas of advanced pathology a positive clinical outcome, and these 
lesions were observed in 38% of those with a positive FOBT who underwent 
colonoscopy. Despite a much higher positivity rate with the !nform test (10% vs 4% 
for Hemoccult II), the probability of detecting significant pathology among those with 
positive FOBT (ie, the positive predictive value) was similar for both tests.  
 
Within the limits of the small number of positive tests in the guaiac arm of this study, 
the rates of cancer detection (10%), adenoma of advanced pathology (30%), and all 
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adenomas (60%) are comparable to other studies using this test.5,7  These studies 
also reported positivity rates for Hemoccult-II of 2.1% and 1%, respectively, 
compared to our 4%.  In a study of biennial screening, 2.7% of patients had cancer 
detected and 29.5% had polyps (details of polyps not given).40 These latter findings 
are similar to those obtained in the present study with the immunochemical test for 
positivity and cancer detection. The interesting difference is the immunochemical kit’s 
high positive predictive value for adenomas, and in particular adenomas of advanced 
pathology.  These test characteristics may be very useful if it is accepted that 
detection and removal of high-risk adenomas is cost effective and likely to reduce 
CRC mortality and morbidity. 
 
Potentially serious complications were reported for 2-3% of colonoscopies and 9% 
reported a range of less significant problems. Although two patients had delayed 
bleeding after polypectomy, each incident was successfully dealt with by 
conservative means. None of the patients required surgery to manage an adverse 
event or to complete a polypectomy. Although these rates of complications from 
colonoscopy may be considered high from a public health perspective, they are 
based on relatively small numbers and are consistent with the large proportion who 
had advanced adenomas removed. A national screening program will need to 
consider the costs of colonoscopy complications against the costs of leaving 
pathology undetected. Complications related to colonoscopy are also increased if 
participants with major co-morbidity are included in screening and referred for 
colonoscopy. One such patient in this series developed heart failure during 
colonoscopy preparation. Further education of GPs regarding the appropriateness of 
referrals for FOBT will be an important component of future screening programs. 
 
This study demonstrates the feasibility of community-based screening for CRC using 
FOBT and highlights some concerns for the proposed national screening program. A 
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moderate level of participation was achieved among community members with 
minimal encouragement. More extensive participation will require awareness raising 
and educational campaigns directed at the community and at health professionals. 
The availability of an immunochemical FOBT contributed to enhanced participation, 
although costs were not taken into consideration.  The proper analysis of 
programmatic costs and potential benefits must take into account a range of 
participation rates, including scenarios where those at greater risk (e.g., men in this 
sample) may be less inclined to undergo screening.  Although the higher positivity 
rate of the immunochemical test necessarily resulted in increased numbers of 
colonoscopies, a moderate positive predictive value was maintained, similar to that 
seen with the guaiac test. Most importantly, infrastructure development for 
colonoscopy services will be crucial if population-based screening is to be 
implemented without lengthy delays and difficult access, particularly outside of capital 
cities and regional centres. 
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Table 1: Distribution of participant characteristics by kit type 
 
Demographic 
characteristic 
Immunochemical 
test
N (%) 
Guaiac test
N (%) 
Total 
 
N (%) 
Gender    
   Female 1273 (52.6) 446 (47.5) 1719 (51.2) 
   Male 1134 (46.9) 493 (52.5) 1627 (48.5) 
   Missing 12 (0.5) 0 (0.0) 12 (0.4) 
Age  
   50-59 years 892 (36.9) 454 (48.3) 1346 (40.1) 
   60-69 years 909 (37.6) 320 (34.1) 1229 (36.6) 
   70-74 years 282 (11.7) 164 (17.5) 446 (13.3) 
   Missing 336 (13.9) 1 (0.1) 337 (10.0) 
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Table 2: Multivariate relationships between participation and gender, age and kit type 
for participants receiving one kit only 
 
 Number 
subjects 
Participation
(%) 
Crude 
OR 
Adjusted 
OR 
95% CI Sig 
Gender   <0.001
   Female 1719 40.4 1.43 1.43 (1.24,1.66) 
   Male 1627 32.1 1.00 1.00 referent 
Age   0.03
   50-59 1346 40.5 0.87 0.87 (0.70,1.08) 
   60-69 1229 38.3 0.79 0.75 (0.60,0.94) 
   70-74 446 43.9 1.00 1.00 referent 
Kit   <0.001
 Immuno-
chemical 
2419 38.7 1.45 1.88 (1.59,2.22)  
Guaiac   939 30.2 1.00 1.00 referent  
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Figure 1: Age differences within kit 
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Table 3: Test outcomes by kit type 
Clinical Results Immunochemical
N (%)
Guaiac 
N (%) 
Overall
N (%)
FOBT Positivity  
   Positives 89 (9.5) 11 (3.9) 100 (8.2)
   Negatives 846 (90.5) 273 (96.1) 1119 (91.8)
   Not analysed 9 1  10
Colonoscopy Outcomea  
   Cancer 2 (2.4) 1 (10.0) 3 (3.3)
   Adenoma advanced pathology 29 (35.4) 3 (30.0) 32 (34.8)
   Other adenoma 26 (31.7) 3 (30.0) 29 (31.5)
   Hyperplastic polyp 10 (12.2) 0 (0.0) 10 (10.9)
   Polyp not otherwise specified 1 (1.2) 0 (0.0) 1 (1.1)
   Diverticular disease 9 (11.0) 1 (10.0) 10 (10.9)
   Haemorrhoids 2 (2.4) 0 (0.0) 2 (2.2)
   Normal 3 (3.7) 2 (20.0) 5 (5.4)
a Categories of colonoscopy outcome do not sum to number of positives because of 
lack of colonoscopy follow-up for some individuals (see results section for more 
detail). 
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Table 4: Multivariate relationships between advanced pathology status (diagnosis of 
cancer or adenoma of advanced pathology) and gender, age and kit type for persons 
completing a kit  
 
 Number 
subjects 
Advanced 
pathology 
(%) 
Crude 
OR 
Adjusted 
OR 
95% CI Sig 
Gender   0.08
   Female 695 2.2 0.56 0.54 (0.27,1.07) 
   Male 523 3.8 1.00 1.00 referent 
Age   0.33
   50-59 545 2.4 1.17 1.10 (0.35,3.41) 
   60-69 471 3.8 1.91 1.79 (0.60,5.38) 
   70-74 196 2.0 1.00 1.00 referent 
Kit   0.10
  Immuno-
chemical 
935 3.3 2.40 2.44 (0.85,6.98)  
  Guaiac 284 1.4 1.00 1.00 referent  
 
 
